









Markets
/
Stocks
/
nasdaq-npce
/

Neuropace Inc

NPCE

10.320USD

+0.430+4.35%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

341.02MMarket Cap

LossP/E TTM



Neuropace Inc

10.320

+0.430+4.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

46 / 207

Overall Ranking

143 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

16.857

Target Price

+70.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 75.54% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 79.91M.

Undervalued

The company’s latest PE is -12.43, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 29.13M shares, decreasing 3.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.37M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.28.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 6.97, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 23.52M, representing a year-over-year increase of 22.14%, while its net profit experienced a year-over-year increase of 15.13%.

Score

Industry at a Glance

Previous score

6.97

Change



Financials

6.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.37

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.54

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.18

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -11.91, which is -76.71% below the recent high of -2.77 and 7.50% above the recent low of -11.02.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/207

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Neuropace Inc is 18.00, with a high of 20.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

16.857

Target Price

+70.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Neuropace Inc

NPCE

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 9.21, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 10.69 and the support level at 8.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

0.24

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.173

Buy

RSI(14)

65.861

Neutral

STOCH(KDJ)(9,3,3)

78.756

Buy

ATR(14)

0.408

High Vlolatility

CCI(14)

122.432

Buy

Williams %R

1.811

Overbought

TRIX(12,20)

0.471

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

9.938

Buy

MA10

9.878

Buy

MA20

9.463

Buy

MA50

9.196

Buy

MA100

10.920

Sell

MA200

11.470

Sell

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 88.81%, representing a quarter-over-quarter decrease of 4.48%. The largest institutional shareholder is The Vanguard, holding a total of 1.37M shares, representing 4.14% of shares outstanding, with 18.01% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Accelmed Growth Partners Management Ltd

4.43M

OrbiMed Advisors, LLC

3.41M

Morgan Stanley & Co. LLC

2.52M

+1.56%

Soleus Capital Management, L.P.

2.61M

+7.19%

BlackRock Institutional Trust Company, N.A.

731.31K

+8.84%

First Light Asset Management, LLC

1.58M

The Vanguard Group, Inc.

Star Investors

1.20M

+13.32%

Armistice Capital LLC

1.15M

+94.67%

Driehaus Capital Management, LLC

803.44K

+235.13%

DWS Investments UK Limited

923.92K

+124.11%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.21, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.91. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.